Novartis and ProFound Therapeutics Launch $775M Collaboration to Develop Novel Cardiovascular Therapies Using AI-Driven Proteomics Platform

June 26,CAMBRIDGE, Mass., ProFound™ Therapeutics, a company pioneering the expansion of the human proteome to develop first-in-class drugs for a range of diseases, announced a four-year research and development collaboration with Novartis to discover and develop new medicines for cardiovascular diseases using its ProFoundry™ platform. This collaboration aims to bring innovative solutions to a growing patient population by combining ProFound's unique capabilities in identifying novel proteins from the expanded proteome as drug candidates and drug targets with Novartis' long-standing commitment and expertise in developing superior cardiovascular medicines to help patients with cardiovascular diseases.Case. (New Frontier! Flagship Launches New Protein Drug Company Completes $75 Million Financing）

Under the terms of the four-year collaboration agreement, ProFound will receive an upfront and near-term milestone payment of $25 million, with a potential deal value of $750 million in downstream milestones for each selected target, and is eligible for additional tiered royalties.

The ProFoundry platform combines multi-layered biological data sources with advanced computational tools to discover, research, and validate the rich protein sources hidden within the expanded human proteome, and to elucidate new protein drugs and drug targets from these findings.

ProFound TherapeuticCEO andFlagship PioneeringJohn Lepore, M.D., Chief Executive Partner, stated:"We are delighted to collaborate with"Novartis Collaboration: Novartis' leadership in cardiovascular innovation is widely recognized across the industry. This collaboration further validates the power of our ProFoundry platform, which goes beyond traditional target discovery methods by leveraging the vast, largely unexplored biology of the expanded human proteome. Together, we have the opportunity to accelerate the discovery of entirely new targets and support the development of transformative therapies to address the growing global burden of cardiovascular disease."

Fiona Marshall, Ph.D., President of Novartis Biomedical Research, stated:"Novartis is committed to identifying new therapeutic targets to drive the discovery and development of innovative drugs for patients with cardiovascular diseases. We are excited to collaborate with ProFound Therapeutics, combining our respective expertise and capabilities to explore underinvestigated biology, uncover novel mechanisms, and translate groundbreaking science into life-changing treatments."